Please use this identifier to cite or link to this item:
https://doi.org/10.1080/14737167.2024.2319607
| Title: | Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore | Authors: | Cheng Ean Chee Jasmeet Singh Khara John Cheong Jek Fong Sivabalan Sivanesan Jian Yi Choy Meibo Hu Amrita Viswambaram Han Chong Toh |
Issue Date: | 22-May-2024 | Publisher: | Taylor & Francis | Citation: | Cheng Ean Chee, Jasmeet Singh Khara, John Cheong, Jek Fong, Sivabalan Sivanesan, Jian Yi Choy, Meibo Hu, Amrita Viswambaram, Han Chong Toh (2024-05-22). Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore. Expert Review of Pharmacoeconomics & Outcomes Research 24 (5) : 631-641. ScholarBank@NUS Repository. https://doi.org/10.1080/14737167.2024.2319607 | Source Title: | Expert Review of Pharmacoeconomics & Outcomes Research | URI: | https://scholarbank.nus.edu.sg/handle/10635/249007 | ISSN: | 1473-7167 | DOI: | 10.1080/14737167.2024.2319607 |
| Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
| File | Description | Size | Format | Access Settings | Version | |
|---|---|---|---|---|---|---|
| 10.108014737167.2024.2319607.zip | 1.66 MB | ZIP | OPEN | None | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.